Autres langues SynAct Pharma AB

Actions

SYNACT

SE0008241491

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm 18:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
17,96 ^SEK	-1,21%		-5,27%	-20,53%

16/09	Le resomelagon de Synact Pharma mis en avant par l'OMS dans la lutte contre la dengue	FW
07/09	Synact s'envole à Stockholm, l'indice OMXS30 progresse de 0,2 %	FW

Autres langues

16/09	WHO identifies resomelagon as one of six dengue drug candidates with evidence supporting further clinical development
10/09	SynAct Pharma to Present at Investing in Life Science on September 22
08/09	SynAct Pharma : Bolagspresentation September 2026
08/09	SynAct Pharma : Company presentation
07/09	SynAct on phase III plans following new ADVANCE data
07/09	SynAct Pharma : Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development – FDA discussions on trial design planned for Q4 2026
07/09	Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development - FDA discussions on trial design planned for Q4 2026
07/09	SynAct Pharma AB Announces Further Analysis Of Phase 2b ADVANCE Study And Supports Phase 3 Development For Resomelagon
03/09	SynAct Pharma : CEO and CSO sell shares
03/09	SynAct Pharma's CEO and CSO sell shares
28/08	SynAct Pharma to present new resomelagon preclinical data on Phase 3-ready RA therapeutic candidate at the 17th World Congress of Inflammation 2026
28/08	SynAct Pharma Presents New Resomelagon Preclinical Data On Phase 3-Ready Ra Therapeutic Candidate At The 17th World Congress Of Inflammation 2026
20/08	SynAct Pharma (Q2 Review): Fenja Financing Backs the Post-ADVANCE Push
20/08	SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	SynAct Pharma publishes Q2 2026 interim results
19/08	SynAct Pharma: Term Sheet Signed for Brazil
19/08	SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed
19/08	SynAct Pharma AB and Hipolabor Farmacêutica LTDA Sign Term Sheet for Co-Development and Commercialization Partnership for Treatment of Dengue In Brazil
06/08	SynAct Pharma Secures Appellate Board Backing in US Patent Application
05/08	SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation
05/08	SynAct Pharma AB Receives Favorable US Patent Decision For Immediate-Release Resomelagon Tablet Formulation
20/07	SynAct Pharma Draws SEK50 Million from New Financing Facility
20/07	SynAct comments on the SEK 100 million facility
20/07	SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness
09/07	Resomelagon shows reduced inflammation and joint damage in osteoarthritis model